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Summary 
Thrombin stimulation of human platelets  results in the release of a preformed proteinaceous 
human eosinophil (Eo)-chemotactic activity.  By the use of different high-performance liquid 
chromatography techniques, two Eo-chemotactic polypeptides (EoCPs), tentatively termed EoCP-1 
and EoCP-2, were purified to homogeneity. Upon SDS-PAGE analysis, these chemotaxins showed 
molecular masses  near  8  kD.  NH2-terminal  amino acid  sequence analysis revealed identical 
sequences for both EoCP-1 and EoCP-2, which are also identical to that of R.ANTES, a cytokine 
that structurally belongs to the interleukin 8 superfamily of leukocyte selective attractants, and 
that is known to be a "memory-type"  T  lymphocyte-selective attractant.  In the major Eo 
chemotaxin, EoCP-1, the residues 4 and 5, which in EoCP-2 were found to be serine residues, 
could not be identified. Electrospray mass spectrometry (ESP-MS) of EoCPs revealed for EoCP-2 
a molecular mass of 7,862.8  _+  1.1 daltons, which is 15.8 mass units higher than the calculated 
value of RANTES, indicating that EoCP-2 is identical to the full-length cytokine, and oxygenation, 
probably at methionine residue number 64, has taken place. Upon ESP-MS, EoCP-1 showed 
an average molecular mass of 8,355  _+  10 daltons, suggesting O-glycosylation at these serine 
residues.  Both natural forms of RANTES showed strong Eo-chemotactic activity (EDs0  --  2 
nM) with optimal chemotactic migration at concentrations near 10 nM, however, there were 
no significant migratory responses with human neutrophils. Chemotactic activity of RANTES 
for human Eos could be confirmed using recombinant material, which has been found to be 
as active as the natural forms. Since R.ANTES gene expression has been detected in activated 
T lymphocytes, and recombinant RANTES was shown to be a "memory" T lymphocyte-selective 
attractant, it is now tempting to speculate about an important role of R.ANTES in clinical situations 
such as allergene-induced late-phase skin reactions in atopic subjects or asthma, where in affected 
tissues both memory T  cells and Eos are characteristic. 
I 
nflammatory diseases are characterized histologically by im- 
migration of different leukocyte subtypes, i.e., neutrophils, 
monocytes/macrophages, T lymphocyte subsets, or eosinophils 
(Eos). Tissue-oriented migration of certain inflammatory ceU 
types assumes, apart from expression of adherence proteins 
and other in vivo migration-fadlitating factors, the existence 
of locally produced cell-selective chemotactic factors. Well- 
described chemotaxins such as C5a or leukotriene B4 are 
chemotactic for a wide variety of leukocytes and do not show 
this specificity. Apart from these pan-leukotactic factors, re- 
cently a number of leukocyte-selective chemotaxins have been 
discovered. 
ID8 represents one of these selective leukocyte attractants, 
which is chemotactic for neutrophils (1) and T lymphocytes 
(2), but not for monocytes and Eos (3, 4).  IL-8 comprises 
a polypeptide mediator that is a member of a superfamily 
of structurally related low molecular weight cytokines, which 
contain four cysteines at identical relative positions with a 
conserved -Cys-X-Cys-(C-X-C)  or -Cys-Cys- (C-C-) motif. 
Members of the C-X-C-subfamily, such as IL-8 (3-5), mela- 
noma growth-stimulatory activity (MGSA/gro oe) (6, 7), and 
neutrophil-activating protein  2  (NAP-2)  (8),  are  potent 
chemotactic factors for neutrophils and in part are also known 
to be chemotactic for lymphocytes, however, not for mono- 
cytes or Eos. 
Members of the C-C-subfamily, monocyte  chemotactic  pro- 
tein I(MCP-1) (9)/monocyte-chemotactic and -activating factor 
(MCAF)  (10), and the cytokine RANTES  (11) represent 
chemotactic factors for monocytes, but not for neutrophils. 
Other members of this subfamily, the human equivalents of 
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for T lymphocyte  subsets, cytotoxic T lymphocytes and naive 
T lymphocytes, respectively, whereas RANTES shows an ap- 
parent selectivity for memory T  lymphocytes (12). 
So  far members of the II-8  superfamily have  not been 
reported to be Eo-chemotactic factors, and hence we address 
the question whether the Ib8 supergene family of low mo- 
lecular mass (6-10 kD) cytokines also contains Eo-selective 
attractants.  We report  here that platelets stimulated with 
thrombin represent a source of Eo-chemotactic proteins, which 
structurally belong to the same superfamily of host defense 
cytokines as a number of other cell-selective chemoattractant 
cytokines do. 
Materials  and Methods 
Recombinant Cytoleines.  Recombinant cytokines RANTES and 
IL-8 were purchased from Pepro Tech Inc. (Rocky Hill, NJ). Purity 
was >98%  as shown by a single line upon SDS-PAGE analysis. 
Isolation of Eosinophils and Neutrophils.  Blood was taken from 
healthy donors or subjects with a mild eosinophilia (5-10% of pe- 
ripheral blood leukocytes).  Eos and neutrophils were isolated from 
acidic citrate dextran-treated blood with the use of discontinuous 
Percoll density gradient centrifugation as previously  described (13). 
Yielded cell preparations were >85% pure for Eos and >95% for 
neutrophils. 
Production  of  Platelet-den'ved  EoCPs.  Platelet-rich  phsma obtained 
from citrate/dextran blood was centrifuged at 2,000 g for 30 rain. 
Phtelet pellets were washed twice with PBS containing 10 mM 
EDTA and resuspended  in PBS. Platdet suspensions  were incubated 
at 37~  for 30 rain in the presence of 2 U/m1 thrombin (Sigma 
Chemical Co., Munich, FRG). After centrifugation at 4~  cell- 
free supernatants were collected and stored below  -70~  until 
further use. 
Purification of  EoCPs.  EoCPs  were purified by HPLC methods 
similar to those used for purification  of NAP-1/IL-8 (3), MGSA/gro 
(6), and platelet-derived  neutrophil attractant (NAP-4) (14). Pooled 
superuatants of thrombin-stimulated phtelets  acidified with tri- 
fluoroacetic  acid (TFA) to pH 3 were concentrated  over filters  (YM5; 
Amicon Corp., Danvers, MA) and applied to a preparative wide- 
pore reversed-phase (RP)-8 HPLC column  (300  x  7 #m  C8 
Nucleosfl, 250  x  12.5 mm; Macherey-Nagel,  Dfiren, FRG). Pro- 
teins were eluted using a gradient of acetonitrih containing 0.1% 
TFA. Fractions active in an Eo chemotaxis system off  RP-8 HPLC 
were pooled, concentrated by lyophilization, and applied to a TSK- 
2000 size exclusion  HPLC column (600 x  8 mm; LKB,  Bromma, 
Sweden) previously equilibrated with 0.1% TFA. Proteins were 
duted with the same solvent. Eo-chemotactic fractions off TSK- 
2000 HPLC were pooled and applied to a wide-pore CN-propyl 
RP HPLC column (5/zm, 250 x 4 mm; J. T. Baker, Gross Gerau, 
FRG) previously  equilibrated  with 0.1% aqueous TFA. Protein elu- 
tion was performed with a gradient of n-propanol containing 0.1% 
TFA. Thereafter, fractions off  CN-propyI-RP-HPLC, which were 
active in the Eo chemotaxis assay system, finally were applied to 
a narrow-pore RP-18-HPLC  column (100 x 7/zm, C18 Nucleosil, 
250 x  10 mm; Macherey-Nagel),  previously  equilibrated  with 0.1% 
aqueous TFA containing 10% (vol/vol) acetonitrile, and polypep- 
tides were duted with a gradient of acetonitrih containing 0.1% 
TFA. 
SDS-PAGE.  SDS-PAGE  analysis  was performed with the Phast 
system (Pharmacia, Freiburg, FRG) using high-density gels ac- 
cording to the manufacturer's instructions. CNBr-cleavage  prod- 
ucts of myoglobin (Sigma Chemical Co.) as well as recombinant 
human Ser72-Ib8 served as molecular mass standards. 
Chemotaxis Assays.  Eo chemotactic activity was measured in 
blind-well Boyden chambers as previously described (13). In some 
experiments Eos were determined microscopically  using a modi- 
fication of Boyden's method as previously described in detail (3, 
13). Chemotactic activity is expressed as chemotactic index, calcu- 
lated as: stimulated migration/random  migration. 
Amino Acid Sequence  Analysis.  Underivatized  samples were ana- 
lyzed using a gas phase sequencer (4701; Applied Biosystems,  Inc., 
Foster City, CA) with on-line HPI.C analysis of the phenylthio- 
hydantoin derivatives. 
Electrospray  Mass Spectrometry  (ESP-MS).  For ESP-MS analysis, 
a Trio-2 quadrupole (VG Biotech-Fisons Instruments LTD, Man- 
chester, UK) was used. The peptides were introduced into the ESP- 
MS ion source as a solution in 50:50:1 methanol/water/acetic acid 
(vol/vol/vol) at a flow rate of 5 #l/min. The electrospray needle 
was held at 4 kV relative to the source. As an internal mass calibrant 
ubiquitine was used. 
Results and Discussion 
To test the hypothesis that 8-1O-kD Eo-specific or -selective 
attractants would exist, we originally used supernatants of 
PBMC preparations that were stimulated with a mixture of 
bacterial LPS and PHA, since these cell preparations are known 
to produce a number of IL-8-1ike chemotactic cytokines such 
as IL-8 itself (3-5,  15), MCP-1/MCAF (16), MGSA/gro c~ 
(6),  and apparently also other chemotactic members of the 
C-C-family (12). 
In initial experiments we detected 6-10-kD Eo-chemotactic 
activity in supernatants of stimulated PBMC (data not shown). 
To determine its origin purified monocytes were stimulated 
with LPS in one experimental series and lymphocyte prepa- 
rations were treated with mitogens in another series. To our 
surprise, in the monocyte supernatants,  which contained high 
amounts of neutrophil-chemotactic II:8, no Eo-chemotactic 
activity could be detected. Instead Eo-chemotactic activity 
was found in  supernatants of PHA-stimulated monocyte- 
depleted lymphocyte preparations (data not shown). 
Because these lymphocyte preparations contained various 
numbers of contaminating platelets, we tested whether these 
cells are a possible source of Eo-chemotactic activity. Platelets 
are known to produce members of the II.-8 supergene family 
such as platelet basic protein and its truncation products, con- 
nective tissue-activating peptide III (CTAP III) as well as 
/3-thromboglobulin (17), which by enzymatic cleavage form 
neutrophil-chemotactic NAP-2 (18). Moreover, platelet factor 
4 (PF-4)  (19), as well as a structurally related molecule we 
tentatively termed NAP-4 (14), are stored in platelets. There- 
fore, it seemed to be an attractive working hypothesis to as- 
sume that platelets also are a source of other members of the 
6-10-kD  cytokine family. 
When lysates of platelets were tested for Eo-chemotactic 
activity in vitro, a high titer of the activity was observed (data 
not shown). To investigate whether this Eo-chemotactic ac- 
tivity is released by physiological stimulation, platelets were 
incubated with thrombin (2 U/ml) for 30 min and superna- 
tants were analyzed for Eo-chemotactic activity. As shown 
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Figure  1.  Eo-chemotactic  activity  in  supernatants  of  thrombin- 
stimulated platelets.  Platelets were incubated at 37~  for 15 rain in the 
presence of thrombin (2 U/rrd). Cell-free supematants were collected, diluted 
in PBS/BSA, and assayed  in the Boyden chamber system for Eo-chemotactic 
activity. The Eo chemotaxin PAF (100 riM) served as control. A typical 
experiment is shown. 
in Fig.  1, a dose-dependent bell-shaped Eo-chemotactic re- 
sponse was observed.  Since platelets  are known to produce 
PAF, a potent Eo chemotaxin of low molecular weight (20), 
the relative molecular mass of this Eo-cbemotactic activity 
was determined. By TSK-2000  size exclusion HPLC,  the 
majority of Eo-chemotactic activity was detected in fractions 
corresponding to the molecular mass range between 5 and 
15 kD (data not shown). To purify the Eo-chemotactic poly- 
peptide(s)  (EoCPs)  present  in  supernatants  of thrombin- 
stimulated platelets, we used similar HPLC methods as those 
with which we purified NAP-1/IL-8 (3), MGSA/gro (6), and 
platelet-derived neutrophil attractant 4  (NAP-4)  (14). 
At the first step, pooled platelet supernatants were chro- 
matographed on a preparative RP-8 HPLC column followed 
by a TSK-2000 size exclusion HPLC (Fig. 2 A). Eo-chemotactic 
material was further purified by wide-pore cyanopropyl HPLC 
and finally purified by narrow-pore RP-18 HPLC (Fig. 2 B). 
The last purification step led to a broad peak of Eo-chemotactic 
activity corresponding to two peaks (EoCP-1  and EoCP-2) 
absorbing at 215 nm (Fig. 2 B). The presence of a single silver- 
stained band upon SDS-PAGE analysis for each EoCP, which 
showed a mobility somewhat higher than that of authentic 
72-residue  II.-8 (molecular weight of 8,532), indicated that 
the material in these EoCP preparations are 8-kD polypep- 
tides (Fig.  2 C). 
NHvterminal amino acid sequencing revealed a single se- 
quence of 16 or 32 residues  for each EoCP: 
EoCP-1,  SPYXXDTTPXXFAYIA 
EoCP-2,  SPYSS  DTTPXXFAYIARPLPRAXXXEYFYXXG 
R.ANTES (21), SPYSS DTTPCCFAYIARPLPRAHIKEYFYTSG... 
The only sequence obtained for both EoCPs in several in- 
vestigations is  identical to  that reported for  the cytokine 
RANTES. 
The molecular weight of EoCP-1 and EoCP-2 was deter- 
mined by ESP-MS (Fig. 3), and obtained values were 8,355 
_+ 10 and 7,862.8  _  1.1, respectively. Although both EoCPs 
showed the same amino acid sequence, EoCP-1 had a molec- 
ular mass approximately 500 mass units higher than that of 
Figure  2.  Purification of EoCPs.  Eo-chemotactic activity detected in 
supernatants of thrombin-stimulated platelets was purified by a series of 
HPLCs. The shaded area represents Eo-chemotactic activity in HPLC frac- 
tions. Experimental conditions are detailed in Materials and Methods. (A) 
TSK-2000 size exclusion I--IPLC  of Eo-chemotactic fractions off  RP-8-HPLC. 
(B) Narrow pore R.P-18-HPLC of an EoCP preparation purified by CN- 
RP-HPLC.  A  representative  purification is  shown.  (C)  SDS-PAGE of 
purified EoCPs. SDS-PAGE analysis was performed with the Phast System 
and proteins were silver stained. In lanes 1 and 7, CNBr cleavage products 
of myoglobin were applied as Mr standards,  whereas lanes 2 and 6 con- 
mined 72-residue rlL-8, and lane 3 contained rKANTES. In lane 4, EoCP-2 
was applied, and lane 5 contained EoCP-1. 
EoCP-2. This difference  could be attributed to O-glycosylation 
presumably at serine residues 4 and 5, where sequence anal- 
ysis of EoCP-1 failed. N-glycosylation sites are known to be 
absent from RANTES (21). The measured molecular mass 
of EoCP-2 agrees well with the calculated  molecular mass 
of R.ANTES. RANTES contains four cysteine amino acids, 
and these are thought to exist in the reduced form, the pep- 
tide being folded with two disulphide bridges, as has been 
proven by 1H-NMR-analysis as well as x-ray crystallographic 
analysis for other members of the KANTES/IL-8 family (22). 
This reduces the calculated molecular weight from 7,851.06 
to 7,847.03.  This value differs from the measured value by 
15.8 units, which can be accounted for by the assumption 
of oxidation having taken place on the single methionine res- 
idue number 67 in RANTES. Oxidation of methionine is 
very common, especially in the case of samples that have been 
exposed to  the atmosphere for any length of time before 
analysis. 
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Figure 3.  ESP-MSofEoCP-2.  The calcuhted  molecular  mass  for EoCP-2 
(E), corrected  for Ubiquitin (U) as an internal standard, is 7,862.8 + 1.1 
chitons. The charge states shown are +4 (1,965.6), +5 (1,572.8), +6 
(1,311.0), and +7 (1,123.8). 
Both EoCP-1 and EoCP-2 showed similar dose-dependent 
Eo-chemotactic activity in the Boyden chamber system (Fig. 
4 a), indicating that derivatization of serine residues 4 and 
5 does not affect Eo-chemotactic activity either in potency 
(EDs0) or efficacy (percent input migrating Eos upon op- 
timal stimulation doses). Moreover, Eo-chemotactic activity 
of RANTES could be confirmed with recombinant mate- 
rial:  rRANTES showed Eo-chemotactic activity at similar 
doses than found for both natural forms (Fig.  4 b). In con- 
trast with this, neither EoCP induced significant migratory 
response of human neutrophils in the Boyden chamber system 
(data not shown). 
RANTES  originally was identified as  an apparently T 
cell-spedfic inducible gene, which was found to be expressed 
by cultured T cell lines that were antigen spedfic and growth 
factor dependent (21). Furthermore, RANTES mRNA ex- 
pression has been found to be inducible in PBL by antigen 
or mitogen stimulation.  It is therefore likely,  but yet not 
proven, that supernatants of mitogen-stimulated PBL con- 
tain Eo-chemotactic RANTES. 
The Eo is one of the predominant cell types found in late- 
phase reactions or at the inflammatory sites in allergic dis- 
eases (23, 24).  Release of cytotoxic cationic Eo granule pro- 
teins as well as synthesis of peptido-leukotrienes are believed 
to contribute to such hypersensitivity diseases. Apart from 
other cytokines such as II.-5 (25), GM-CSF (25), and "lym- 
phocyte chemotactic factor LCF" (26), RANTES has been 
identified as an Eo-selective attractant in vitro and might par- 
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Figure 4.  Eo-chemotactic  activity  of EoCPs and rRANTES. (a) Both 
RP-18-HPLC-purified  fractions, EoCP-1 (Q) and EoCP-2 (O), were  ana- 
lyzed for Eo-chemotactic  activity. Results are expressed as mean + SE 
from six (EoCP-1) and five  (EoCP-2) experiments. (b) Eo-ehemotactic  ac- 
tivity ofrRANTES. Results are expressed  as mean _+ SE from  five  experi- 
ments. PAF (100 nM) served  as control. 
ticipate in recruitment of Eos to T cell-mediated hypersensi- 
tivity reactions in vivo.  Since it is known that rRANTES 
attracts T  lymphocytes of the memory type (CD45RO +) 
(11), RANTES may be a common mechanism in diverse im- 
munological reactions, which culminate in the emigration 
of T lymphocytes of this phenotype and Eos from the circu- 
lation into sites of inflammation. The allergen-induced late- 
phase skin reaction in atopic subjects, in which both memory 
T cell infiltration and Eo accumulation are characteristic (24, 
27), may represent a possible clinical example. 
Our finding that platelets release upon stimulation Eo- 
chemotactic RANTES serves as additional evidence for the 
recent understanding that platelets contribute to inflamma- 
tory reactions (reviewed in reference 28).  From guinea pig 
models it was suggested that platelets are a prerequisite com- 
ponent in allergic asthma, since platelet depletion reduced 
Eo infiltration into the lung after PAF or allergen exposure 
to sensitized animals (29). Moreover, bronchial Eo accumula- 
tion was reduced without a significant change in neutrophil 
infiltration  after  antigen  challenge  in  thrombocytopenic- 
allergic rabbits compared with control animals (30). It is there- 
fore tempting  to  speculate  that  RANTES  released from 
platelets might play a role for selective Eo infiltration after 
antigen challenge in these situations. 
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